Curative-Intent Treatment with Durvalumab in Early-Stage Cancers

The introduction of immunotherapy has fundamentally transformed the treatment landscape in cancer, providing long-term survival benefit for patients with advanced disease across multiple tumor types, including non-small cell lung cancer (NSCLC). In the placebo-controlled phase 3 PACIFIC trial, the P...

Descripción completa

Detalles Bibliográficos
Autores principales: Melillo, Giovanni, Chand, Vikram, Yovine, Alejandro, Gupta, Ashok, Massacesi, Cristian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190020/
https://www.ncbi.nlm.nih.gov/pubmed/33881745
http://dx.doi.org/10.1007/s12325-021-01675-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190020/
https://www.ncbi.nlm.nih.gov/pubmed/33881745
http://dx.doi.org/10.1007/s12325-021-01675-0

Ejemplares similares